













Diagnosis and quantitative detection of HSV DNA 
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ABSTRACT
Diagnosis of herpes simplex encephalitis (HSE) is based on the detection of herpes simplex virus 
(HSV) DNA in patients’ CSF samples. HSV DNA quantitation has the potential for estimating the 
effects of antiviral therapy. The aim of this study was to diagnose HSV DNA in HSE suspected pa-
tients and the quantitative analysis of its genome using real-time PCR to assess the value of the viral 
load in the course of antiviral treatment. The CSF samples were collected from 236 consecutive HSE 
suspected patients from November 2004 to May 2008. Upon DNA extraction, the samples were ana-
lyzed by Real-Time PCR assay. A set of primers amplified a common sequence of HSV glycoprotein 
B gene. The copy numbers of unknown samples were expressed via a standard curve drawn with a 
known amount of amplified cloned plasmid. Of the 236 samples, 137 (58%) came from males and 
99 (42%) from females. The HSV genome was detected in 22 (9.3%) patients by PCR, 13 males/ 
9 females. Serial CSF samples were available from 10 of the 22 patients. The range of the HSV DNA 
copy numbers in the clinical samples ranged from 2.5 × 102 to 1.7 × 106 copies/mL of CSF. Quantita-
tive PCR results can be helpful in evaluating the efficacy of antiviral therapy in the above-mentioned 
patients. There is an association between the initial viral load and the duration of treatment course. 
Keywords: encephalitis; herpes simplex; viral load; acyclovir; quantitative analysis.
[Braz J Infect Dis 2011;15(3):211-214]©Elsevier Editora Ltda.
INTRODUCTION
Herpes simplex encephalitis (HSE) is the most 
common form of sporadic viral encephalitis; 
but it is still an uncommon disease, with an esti-
mated incidence of 1 in 250,000 to 1 in 500,000 
persons per year.1,2 Acute HSE is associated with 
high morbidity and mortality. In untreated pa-
tients or those on ineffective antiviral therapy, 
the mortality is approximately 70% and out of 
surviving patients, important neurologic se-
qualae occurs in nearly 97%.3 Early diagnosis 
and use of acyclovir as a therapeutic agent are 
highly effective in reducing the mortality rate 
due to HSE; however, permanent neurologic 
complications are common in survivors.4 Her-
pes simplex virus (HSV) DNA detection by 
PCR assay of cerebrospinal fluid (CSF) samples 
is very efficient in establishing the diagnosis of 
HSE and has become the diagnostic method 
of choice.5-7 It is a reliable method, highly sensitive 
and specific. Quantitative HSV-PCR can be used 
to monitor the effect of treatment,8 but its correla-
tion with prognosis has not been established.9
The aim of the present study was to evalu-
ate HSV DNA in the CSF of the HSE suspected 
patients, as well as the effect of acyclovir thera-
py on the number of HSV DNA copies in CSF 
by a Real-Time TaqMan probe PCR.
MATERIALS AND METHODS
Patients
In the present study, 236 consecutive patients 
older than 16 years with suspected HSE were 
prospectively enrolled. The patient sample in-
cluded 137 (58%) men and 99 (42%) women, 
with ages ranging between 16 and 81 years 
(mean ± standard deviation: 44.24 ± 15.45 
years). The patients’ CSF specimens were sub-
mitted to the Professor Alborzi Clinical Mi-
crobiology Research Center, Namazi Hospital, 
Shiraz, Iran from November 2004 to May 2008 
for diagnosis of HSV infection. The inclusion 
criteria were behavioral abnormality, progres-
sive alteration of sensorium, focal or general-
ized seizures with or without focal neurological 
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deficit, preceded by a history of prodromal phase of head-
ache, fever and other constitutional symptoms. The initial 
samples were drawn from 0 to 5 days after the onset of clini-
cal symptoms, before treatment. In the PCR positive pa-
tients, CSF samples were obtained before treatment, as well 
as whenever possible during treatment. CSF specimens were 
kept at -20°C until PCR assay.
Empirical treatment with acyclovir was started for eve-
ry patient with suspected HSE, while waiting for the PCR 
result. Acyclovir therapy continued for patients with posi-
tive PCR results and also for a few patients whose physi-
cians decided to administer treatment based on clinical 
findings and other workups like focal electroencephalo-
graphic (EEG), computed tomography (CT), and/or mag-
netic resonance imaging (MRI) results (intravenous acy-
clovir, 30 – 40 mg/kg/day, for 8 – 21 days).
Nucleic acid extraction
DNA was extracted from 200 µL of CSF using spin-column 
based QIAamp Mini Kit (Quiagen, Hilden, Germany). 
Extraction protocol for CSF was used as indicated by the 
manufacturer.
Real-Time PCR
The Real-Time quantitative PCR was performed with oli-
gonucleotide primer pairs and probe specific for the type-
common region of HSV-1 and HSV-2 glycoprotein B (gB), 
as reported previously.10 The primers used were HSV-FP 
(5´- TCC CGG TAC GAA GAC CAG-3´) and HSV-RP (5´- 
AGC AGG CCG CTG TCC TTG-3´), and the probe was 
HSV-TCP (5´-FAM-TGG TCC TCC AGC ATG GTG ATG 
TTG/C AGG TCG-TAMRA-3´). Amplification was carried 
out in an Applied Biosystem Sequence Detector 7500 ma-
chine, programmed for a four-step protocol: 2 min of in-
cubation at 50°C for AmpErase activation, 10 min at 95°C 
for polymerase activation and for 45 cycles: 15 s at 94°C for 
denaturation, 60 s at 58°C for annealing, extension and data 
collection. Each 50 µL-PCR mixture contained 10 µL of pu-
rified DNA, 840 nM concentrations of each primer, and 100 
nM probe in 1x TaqMan universal PCR master mix (Applied 
Biosystems, Branchburg, New Jersey USA). Negative con-
trols were included in the extraction process between every 
20 clinical samples. All negative samples were tested twice. 
Target amplicons were produced based on a standard 
PCR protocol by the above-mentioned primer sets and sep-
arated on agarose gel, then extracted and purified from gel 
and cloned into the pTZ57R vector (Fermentas UAB, Vilni-
us, Lithuania).11 The plasmid containing the target sequenc-
es was purified using a commercial kit (Fermentas UAB, 
Vilnius, Lithuania) and its concentration was determined 
spectrophotometrically. Quantification was carried out by 
drawing standard curves using the serially diluted pTZ57R 
plasmid containing the target amplification product. Six 
positive control standards at 101, 102, 103, 104, 105 and 106 
copies/reaction were used. The drawn standard curve was 
linear in 10 to 106 copies/reaction of the virus (R2 = 0.98). 
The copy numbers of the clinical samples were calculated 
automatically by applied biosystem sequence detection soft-
ware v 1.3.1.
Statistical analysis
Descriptive statistic, Pearson Chi-square test, independent 
two tailed t-test, paired t-test and Wilcoxon signed ranks 
test were used for analysis of the data; p-value of less than 
0.05 was considered significant. SPSS version 15 (Chicago, 
IL, USA) was used for statistical analysis.
RESULTS
Among the 236 patients enrolled in this study, 22 (9.3%) had 
positive PCR results. Thirteen PCR positive patients were 
male and 9 were female. Sequential CSF samples were avail-
able for 10 patients. HSV DNA was detected in a total of 
34/42 (81%) CSF samples from these 22 patients. The demo-
graphic data and laboratory findings are shown in Table 1. 
No correlation was found between age, gender and positive 
PCR results (p > 0.05).
The copy number of HSV DNA, measured by the real-
time PCR assay, ranged from 2.5 × 102 to 1.7 × 106 copies/mL 
in the initial CSF samples; median 4.8 × 104 copies/mL. Viral 
load in the initial CSF specimens of patients 29 and 77, with 
more than one sample for each, appeared lower than that in 
the second obtained sample. In both patients, the virus be-
came undetectable, following a 21-day antiviral treatment. 
Nevertheless, the comparison of viral loads between the first 
and second samples, obtained from all patients, showed a 
decline in the latter (p = 0.047).
In patients with serial samples the initial viral load in 
CSF was positively correlated with the duration of the acy-
clovir treatment course (p = 0.014). Although no statistically 
significant correlation was found between the initial viral 
load in CSF and the number of positive PCR results, the data 
shown in Table 1 are somehow indicative of such a correla-
tion, i.e., the greater the load, the longer the PCR remains 
positive during the course of treatment.
DISCUSSION
In this report, an in-house Real-Time quantitative PCR was 
used to detect the HSV DNA in CSF samples of 236 HSE 
suspected patients, and the amount of HSV DNA in the CSF 
samples from 22 HSE patients was measured. Age, gender and 
duration of acyclovir treatment with PCR positivity and/or 
levels of viral DNA loads were compared. Also, the effect of 
acyclovir therapy on the HSV DNA load is shown for 10 pa-
tients.
As reported in previous studies, if CSF specimens are col-
lected within a couple of days after the onset of clinical mani-
festations and when CSF protein and white blood cell count 
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Table 1. Demographic data and laboratory findings of the 22 patients with herpes simplex virus encephalitis
Patient Sex Age  CSF   Initial CSF Initial CSF Duration of No. of Viral 
   no.  (yr) collection  leukocyte total protein  acyclovir samples loads 
   after the on cell count (mg/dL) therapy  (copies/mL) 
   set (day)  (/mL)  (day)
 6 F 55 3 134 103 14 1 3.7 × 104
 10 F 43 2 300 98 14 1 4.1 × 104
 25 M 26 1 460 135 8 1 2.5 × 102
 29 M 47 1 57 35 21 4 1.6 × 104
         2.1 × 104
         1.5× 103
         0
 40 M 32 0 65 58 14 1 8.5 × 103
 44 M 57 2 525 316 21 3 1.7 × 106
         4.5 × 105
         3.9 × 104
 55 F 44 2 137 120 14 1 7.2 × 104
 65 F 26 1   9 1 3.4 × 103
 77 F 24 0 140 90 21 4 6.7 × 104
         8.1 × 104
         2.8 × 102
         0
 95 M 30 1 78 53 16 1 1.8 × 105
 105 M 62 3 113 88 21 1 1.3 × 106
 115 M 80 2 22 97 14 3 6.9 × 104
         5.4 × 103
         0
 132 M 40 0 17 65 8 2 2.7 × 103
         0
 135 F 41 2 75 93 10 2 4.1 × 103
         0
 139 M 68 1 235 172 18 3 2.8 × 104
         1.3 × 104
         4.2 × 102
 156 F 35 2 502 43 21 4 3.9 × 105
         2.7 × 103
         7.8 × 102
         0
 169 M 26 2 421 76 18 1 8.3 × 105
 186 F 22 3 160 81 9 2 5.6 × 103
         0
 193 M 50 2 193 88 14 3 6.6 × 104
         8.4 × 103
         0
 206 M 44 1 6 35 16 1 5.5 × 104
 218 F 58 2 25 93 14 1 4.3 × 105
 232 M 61 3 12 84 8 1 5.7 × 103
F, female; M, male; CSF, cerebrospinal fluid.
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are not highly elevated, the PCR test in HSE patients may turn 
out negative.12,13 In the present study, there were some cases 
with a negative PCR test for which the antiviral treatment was 
pursued, based on the clinical grounds, MRI or CT scan find-
ings. Although in most HSE cases the PCR result is positive, 
PCR negative infections have also been described.14,15 In view 
of the fact that clinical and imaging findings cannot always 
serve as the basis for a definitive diagnosis of HSE,16,17 it could 
be suggested that a second sample be collected and examined 
two days thereafter if the initial HSV PCR test was negative. In 
doing so, the chance of false negative results in the HSE diag-
nosis is reduced. Acyclovir therapy for HSE patients is usually 
successful and improves patient outcome.18 Moreover, resist-
ance to acyclovir in an immunocompetent individual from 
our region has not been reported.19 Of the 10 patients with se-
quential CSF samples, treatment with acyclovir led to success-
ful virus elimination in eight patients and in the remaining 
two it severely reduced viral load. Thus, all of them responded 
clinically to acyclovir therapy. The results also showed that 
duration of antiviral therapy of less than 8 days does not turn 
the positive PCR results negative.
There are a few reports indicating a correlation between the 
initial HSV DNA load and the patents’ outcomes.16 However, 
the majority of the literature on HSE patients reveals no asso-
ciation between the initial load of HSV DNA in CSF and the 
respective outcomes.8,9,20,21 Although the present study avoided 
the analysis of the patients’ outcomes, the results could be in-
dicative of some association between the initial viral load and 
the number of subsequent positive PCR results and, more im-
portantly, the duration of treatment. Also, it could be suggested 
that antiviral therapy should not be discontinued unless the 
PCR result becomes negative during treatment.
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